Chapman, Roger W.

International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis

Alvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology

Liver Diseases and ImmunityIgG4-Related and Inflammatory Diseases

Cited by 2,903

Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue

Boberg, K. M., Chapman, R. W., Hirschfield, G. M., Lohse, A. W., Manns, M. P., & Schrumpf, E. (2011) · Journal of Hepatology

Liver Diseases and ImmunityIgG4-Related and Inflammatory Diseases

Cited by 555

Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis

Weismüller, T. J., Trivedi, P. J., Bergquist, A., Imam, M., Lenzen, H., Ponsioen, C. Y., Holm, K., Gotthardt, D., Färkkilä, M. A., Marschall, H.-U., et al. (2017) · Gastroenterology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 533

Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis

The UK-PSCSC Consortium, Liu, J. Z., The International IBD Genetics Consortium, The International PSC Study Group, Hov, J. R., Folseraas, T., Ellinghaus, E., Rushbrook, S. M., Doncheva, N. T., Andreassen, O. A., et al. (2013) · Nature Genetics

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 391

Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease

The UK-PSC Consortium, Ji, S.-G., The International IBD Genetics Consortium, The International PSC Study Group, Juran, B. D., Mucha, S., Folseraas, T., Jostins, L., Melum, E., Kumasaka, N., et al. (2017) · Nature Genetics

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 357

A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis

Mitchell, S. A., Bansi, D. S., Hunt, N., Bergmann, K. V., Fleming, K. A., & Chapman, R. W. (2001) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 351

The natural history of small-duct primary sclerosing cholangitis

Björnsson, E., Olsson, R., Bergquist, A., Lindgren, S., Braden, B., Chapman, R. W., Boberg, K. M., & Angulo, P. (2008) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 305

norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis

Fickert, P., Hirschfield, G. M., Denk, G., Marschall, H.-U., Altorjay, I., Färkkilä, M., Schramm, C., Spengler, U., Chapman, R., Bergquist, A., et al. (2017) · Journal of Hepatology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 297

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis

Kowdley, K. V., Luketic, V., Chapman, R., Hirschfield, G. M., Poupon, R., Schramm, C., Vincent, C., Rust, C., Parés, A., Mason, A., et al. (2018) · Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 281

Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease

Muir, A. J., Levy, C., Janssen, H. L. A., Montano‐Loza, A. J., Shiffman, M. L., Caldwell, S., Luketic, V., Ding, D., Jia, C., McColgan, B. J., et al. (2019) · Hepatology

Liver Diseases and ImmunityLiver physiology and pathology

Cited by 195

Randomized Clinical Trial: Macrogol/PEG 3350 Plus Electrolytes for Treatment of Patients With Constipation Associated With Irritable Bowel Syndrome

Chapman, R. W., Stanghellini, V, Geraint, M., & Halphen, M. (2013) · American Journal of Gastroenterology

Gastrointestinal motility and disordersPelvic floor disorders treatments

Cited by 180

Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score

Carbone, M., Nardi, A., Flack, S., Carpino, G., Varvaropoulou, N., Gavrila, C., Spicer, A., Badrock, J., Bernuzzi, F., Cardinale, V., et al. (2018) · The Lancet Gastroenterology & Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 155

High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective

Cullen, S. N., Rust, C., Fleming, K., Edwards, C., Beuers, U., & Chapman, R. W. (2008) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 136

Obeticholic acid-a new therapy in PBC and NASH

Chapman, R. W., & Lynch, K. D. (2020) · British Medical Bulletin

Liver Diseases and ImmunityLiver Disease Diagnosis and Treatment

Cited by 116

Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases

Lynch, K. D., Chapman, R. W., Keshav, S., Montano-Loza, A. J., Mason, A. L., Kremer, A. E., Vetter, M., de Krijger, M., Ponsioen, C. Y., Trivedi, P., et al. (2020) · Clinical Gastroenterology and Hepatology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 105

Antibodies to SS‐A/Ro‐52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis

GRANITO, A., MURATORI, P., MURATORI, L., PAPPAS, G., CASSANI, F., WORTHINGTON, J., FERRI, S., QUARNETI, C., CIPRIANO, V., DE MOLO, C., et al. (2007) · Alimentary Pharmacology & Therapeutics

Liver Diseases and ImmunitySystemic Lupus Erythematosus Research

Cited by 102

Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease

Næss, S., Björnsson, E., Anmarkrud, J. A., Mamari, S. A., Juran, B. D., Lazaridis, K. N., Chapman, R., Bergquist, A., Melum, E., Marsh, S. G. E., et al. (2014) · Liver International

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 54

Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis

Hedin, C. R. H., Sado, G., Ndegwa, N., Lytvyak, E., Mason, A., Montano-Loza, A., Gerussi, A., Saffioti, F., Thorburn, D., Nilsson, E., et al. (2020) · Clinical Gastroenterology and Hepatology

Inflammatory Bowel DiseaseLiver Diseases and Immunity

Cited by 52

A 2-year follow-up study of anti-neutrophil antibody in primary sclerosing cholangitis: relationship to clinical activity, liver biochemistry and ursodeoxycholic acid treatment

Lo, S. K., Fleming, K. A., & Chapman, R. W. (1994) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 50

Small duct primary sclerosing cholangitis

Chapman, R. W. (2002) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 14

Experience from the First UK Inter-Regional Specialist Multidisciplinary Meeting in the Diagnosis and Management of IgG4-Related Disease

Goodchild, G., Peters, R. J., Cargill, T. N., Martin, H., Fadipe, A., Leandro, M., Bailey, A., Collier, J., Firmin, L., Chouhan, M., et al. (2020) · Clinical Medicine

IgG4-Related and Inflammatory DiseasesSystemic Sclerosis and Related Diseases

Cited by 13

964 THE FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) INCREASES PLASMA FGF-19 CONCENTRATIONS AND DECREASES BILE ACID SYNTHESIS IN PRIMARY BILIARY CIRRHOSIS (PBC)

Marschall, H.-U., Luketic, V., Lovgren-Sandblom, A., Benthin, L., Kowdley, K., Hirschfield, G., Mason, A., Lindor, K., Gordon, S., Vincent, C., et al. (2012) · Journal of Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 9